Stock ELVN ENLIVEN THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Enliven Therapeutics, Inc.

Equities

ELVN

US29337E1029

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-10 pm EDT 		5-day change 1st Jan Change
23.43 USD -1.97% Intraday chart for Enliven Therapeutics, Inc. +11.62% +69.29%
Apr. 11 Enliven Therapeutics, Inc. Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia CI
Apr. 09 Enliven Therapeutics, Inc. Appoints Lori Kunkel to Board of Directors CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Enliven Therapeutics Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia
AQ
Enliven Therapeutics, Inc. Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia
CI
Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of Directors
AQ
Enliven Therapeutics, Inc. Appoints Lori Kunkel to Board of Directors
CI
Mizuho Securities Initiates Enliven Therapeutics With Buy Rating, Price Target is $34
MT
Enliven Therapeutics, Inc. announced that it has received $90.000014 million in funding
CI
Enliven Therapeutics to Share Initial Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 and Host Virtual Key Opinion Leader Event on April 11, 2024
AQ
North American Morning Briefing : Investors -2-
DJ
Enliven Therapeutics Announces $90 Million Private Placement Financing and Provides Pipeline Updates
AQ
Enliven Therapeutics, Inc. announced that it expects to receive $90.000014 million in funding
CI
Enliven Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Enliven Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update
AQ
Enliven Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Enliven Therapeutics to Present at TD Cowen’s 44th Annual Health Care Conference
AQ
Enliven Therapeutics, Inc.(NasdaqGS:ELVN) added to NASDAQ Biotechnology Index
CI
Enliven Therapeutics Q3 Loss Narrows
MT
Enliven Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Enliven Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update
AQ
Enliven Therapeutics Insider Sold Shares Worth $104,999, According to a Recent SEC Filing
MT
Enliven Therapeutics Insider Sold Shares Worth $111,751, According to a Recent SEC Filing
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ELVN Stock
  4. News Enliven Therapeutics, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW